Evidence map›Paper›PMID 34389926›Full record

ArticleBreast cancer research and treatment2021

Myosteatosis at diagnosis is adversely associated with 2-year survival in women with estrogen receptor-negative metastatic breast cancer.

Patricia Sheean, Sandra Gomez-Perez, Cara Joyce, Paula O'Connor, Monica Bojko, Amber Smith, Vasilios Vasilopoulos, Ruta Rao, Joy Sclamberg, Patricia Robinson

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Patricia SheeanLoyola University Chicago, 2160 South First Avenue, Building 115, Room 344, Maywood, IL, 60153, USA. psheean1@luc.edu.ORCID http://orcid.org/0000-0003-0032-514X
Sandra Gomez-PerezRush University, 600 S. Paulina Street 737D AAC, Chicago, IL, 60612, USA.
Cara JoyceLoyola University Chicago, 2160 South First Avenue, Building 115, Room 254, Maywood, IL, 60153, USA.
Paula O'ConnorLoyola University Chicago, 2160 South First Avenue, Building 115, Room 344b, Maywood, IL, 60153, USA.
Monica BojkoRush University Medical Center, 1653 W Congress Parkway, Chicago, IL, 60612, USA.
Amber SmithRush University Medical Center, 1653 W Congress Parkway, Chicago, IL, 60612, USA.
Vasilios VasilopoulosLoyola University Medical Center, 2160 South First Avenue, Maywood, IL, 60153, USA.
Ruta RaoRush University Medical Center, 1620 W. Harrison, Chicago, IL, 60612, USA.
Joy SclambergRush University Medical Center, 1620 W. Harrison, Chicago, IL, 60612, USA.
Patricia RobinsonLoyola University Medical Center, 2160 South First Avenue, Maywood, IL, 60153, USA.
Rush University Medical Center · USLoyola University Chicago · USLoyola University Medical Center · USRush University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo examine the relationship between skeletal muscle (SM) and cancer-specific outcomes for women with estrogen receptor-negative (ER-) metastatic breast cancer (MBC).

methodsFor this retrospective cohort, females (≥ 18 years) with histologically confirmed ER- MBC and computerized tomography (CT) imaging were screened. Demographic, anthropometric, and clinical data were collected uniformly from the electronic medical record. CT images inclusive of the third lumbar region (L3) at diagnosis, 6 and 12 months, were used to classify sarcopenia (≤ 41 cm

resultsParticipants were 58.0 (15.0) years of age, ethnically diverse (55% non-Hispanic white, 31% Black, 11% Hispanic), post-menopausal (73%, n = 111), and classified as overweight (BMI 29.4 (7.6)). At diagnosis, 40% (n = 61) were sarcopenic, 49% had myosteatosis, and 28% (n = 42) had both. While Cox PH modeling and RMST analysis reveal no significant relationship between sarcopenia at diagnosis and 2-year survival (RMST difference - 1.6 (1.4) months, HR 1.35 (0.88-2.08)), these analyses support a significant, adverse association between myosteatosis at diagnosis and 2-year survival (RMST difference - 2.4 (1.5) months, HR 1.72 (1.09-2.72)). Incident sarcopenia was 11% (n = 5/45) and 2.5% (n = 1/40), respectively, while incident myosteatosis was 19% (n = 8/42) and 15% (n = 5/34) at 6 and 12 months, respectively. TTP and treatment toxicities did not appear to be related to diagnostic SM or body composition changes over time.

conclusionTargeted interventions initiated within the first year of diagnosis to preserve or improve SM quality seem warranted for women with ER-MBC.

Indexed as

Breast NeoplasmsSarcopeniaBody CompositionFemaleHumansMuscle, SkeletalReceptors, EstrogenRetrospective StudiesReceptors, EstrogenEpidemiologyMetastatic breast cancerMyosteatosisSarcopeniaSkeletal muscle

Identifiers

PMID34389926
OpenAlexW3191208021

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.